跳至主要内容
临床试验/NCT02158195
NCT02158195已完成不适用

Immunopathology of Autoimmune Hemolytic Anemia: an Open, Prospective and Multicenter Study

Centre Hospitalier Universitaire Dijon5 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2013年7月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
27
试验地点
5
主要终点
physiological parameter : percentage of inhibiting LT proliferation inhibition

研究概览

简要总结

Autoimmune hemolytic anemia (AIHA) is an auto-immune disease mediated by specific antibodies targeting red blood cells. Its pathogenesis is not completely understood, and the role of T cells have been rarely studied.

The aim of this study is to compare the frequency of circulating T cells, T cell polarization and functions, notably regulatory T cells, during warm AIHA by comparison to healthy controls.

The role of treatments, such as steroids, will also be determined in patients with warm AIHA.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with primary warm Autoimmune Hemolytic Anemia (wAIHA)
  • Secondary AHAI (infections, hematological diseases, systemic diseases)
  • Naive of treatment for hemolytic anemia or in relapse
  • Older than 16
  • Able to understand written and spoken French
  • who have provided written informed consent
  • INCLUSION CRITERIA for CONTROLS
  • Persons without auto-immune disease, cancer or active infection.
  • Older than 16
  • Able to understand written and spoken French
  • who have provided written informed consent

排除标准

  • Cold agglutinin disease
  • Pregnancy
  • Persons without national health insurance
  • Exclusion Criteria for Controls:
  • Subjects treated with corticosteroids or immunosuppressants
  • Pregnancy
  • Persons without national health insurance

研究组 & 干预措施

Patients

干预措施: blood samples (Biological)

controls

干预措施: blood samples (Biological)

结局指标

主要结局

physiological parameter : percentage of inhibiting LT proliferation inhibition

时间窗: Change from baseline to 3 months

physiological parameter : blood level of regulatory T cells (Treg, CD4+CD25HighFoxp3+)

时间窗: Change from baseline to 3 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验